WebinarsNew
Deep DiveNew
Explore Business Standard
The saga surrounding former Nvidia CEO Jensen Huang has riveted Silicon Valley like few other stories, from reports of extramarital affairs to his resignation last week and short-lived comeback bid. Huang and Nvidia, a computer chip company that has been driving the AI boom, were top of mind this week at Semafor's Silicon Valley; The World forum, a gathering of tech executives, investors, policymakers and government officials. Here is what prominent business leaders and officials in attendance had to say about the episode and its aftermath. Sam Altman -------------- Altman, co-founder and CEO of OpenAI, said Monday at the forum that he feels "personal strong empathy" for Huang in the wake of his resignation. Altman, who himself was removed as CEO in 2023 before being quickly reinstated, said that he doesn't think he knows enough to answer the question of whether Huang should return to Nvidia, but said "Jensen has long been a hero of mine." "Heroes have flaws. I am grateful for th
Nvidia Chairman Harvey Jones said Tuesday that the company's board of directors does not intend to reinstate Jensen Huang as CEO, a statement that came hours after Huang said he would come back to lead the chipmaker if the board invited him. It was Huang's first public statement since he abruptly left the company last week following revelations of an extramarital affair with an alleged Chinese spy. Huang said in a social media post that if the board decided that his return was in the best interest of shareholders, employees, the company and the country, he would be "honoured to answer these calls." He acknowledged making "serious mistakes" in his personal life. Some tech industry figures, including SpaceX and Tesla CEO Elon Musk, have called for the reinstatement of Huang, a high-profile booster for the artificial intelligence industry who oversaw Nvidia's development as the key provider of chips driving advanced AI models. President Donald Trump, a Huang ally who has spoken with hi
Artificial Intelligence (AI) has the potential to drastically cut the time required to take a drug molecule from the lab to patients, compressing the current five-to-seven-year timeline into just one or two years, Kiran Mazumdar-Shaw of Biocon said on Tuesday. Speaking on the role of AI in life sciences, Shaw, the Executive Chairperson, Biocon Ltd, noted that accelerating this journey from lab to clinic will unlock major opportunities in precision and personalised medicine. "Ultimately the process of drug development doesn't end in the labs. It has to be validated in clinical trials. How do you pick the right patients? How do you conduct these trials in a way that gives you early readouts? "This is all what AI is going to be used for in the future. So today it takes you almost five to seven years to get a molecule from lab all the way to the patients. Can we compress that into a year or two? That is going to be the most fascinating outcome and impact," she said on the first day of t
Killer robots and drones come up for a reckoning this week as government envoys rev up a discussion and could decide whether to launch negotiations toward setting rules for the use of the deadly machines -- or not. Pope Leo XIV, the UN chief and advocacy groups cast the issue as an existential debate: Whether robots can be allowed to kill and whether humans must maintain some control of and accountability for the use of lethal autonomous weapon systems. Activists say armed drones that can independently strike targets have already been deployed in some select instances in conflict zones like Ukraine and the Middle East, but widespread rollout hasn't happened. Scary would-be scenarios, like armed drones flying amok and gunning down civilians with pinpoint precision, have peppered years of discussions about killer robots. But those talks haven't produced any international restrictions. The United States and Russia, longtime rivals, want to limit any curbs on their abilities to develop